ClinicalTrials.gg
CompletedNCT03920267Updated Mar 20, 2026Results posted

Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus

A Phase 2 interventional study of BMS-986165 in Systemic Lupus Erythematosus, sponsored by Bristol-Myers Squibb. Completed at 98 sites in 14 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
261
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb — 5 open to participants now, 9 under way, 3 of them phase 3. Lupus Erythematosus, Systemic · Bristol-Myers Squibb.

Enrollment
8th of 19
261 · median 125
Started
2019
the only one that year
Phase 2
7 of 20
none open now
Registered
9th of 20
by date

Among the 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb, this one is the 8th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2019, is one of 7 in phase 2, and was the 9th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

5 of the 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The main objective of the trial is to characterize the long-term safety and tolerability of BMS-986165 in subjects with Systemic Lupus Erythematosus (SLE).

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • Systemic Lupus Erythematosus
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completion of SLE Study (NCT03252587) through the protocol-required treatment period, and currently receiving blinded study drug. Note: If a subject is not receiving blinded study drug due to exceptional circumstances (eg, missed product [IP] due to COVID-19 pandemic, delays in study approval, etc), the subject may be allowed to enroll with approval from the BMS Clinical Trial Physician or designee.

Exclusion criteria

Exclusion Criteria:

  • Any disease or medical condition that, in the opinion of the investigator, would make the subject unsuitable for this study, would interfere with the interpretation of subject safety or study results, or considered unsuitable by the investigator for any other reason
  • Evidence of active tuberculosis (TB)

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
261 participants (actual)

Study arms

  • Experimental
    BMS-986165 Dose 1

    Drug: BMS-986165

  • Experimental
    BMS-986165 Dose 2

    Drug: BMS-986165

  • Experimental
    BMS-986165 Dose 3

    Drug: BMS-986165

Interventions

  • Specified dose on specified days

    Also known as: Deucravacitinib

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events and Treatment Emergent Serious Adverse Events

    A Treatment-Emergent Adverse Event (TEAE) is any untoward medical occurrence that begins or worsens after the first dose of study treatment, including any unfavorable sign, symptom, disease, or abnormal lab finding, whether or not related to the product, and may include worsening of pre-existing conditions. A Serious Adverse Event (SAE) is any untoward medical occurrence that results in death, is life-threatening, requires or prolongs hospitalization, causes persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect, or is considered an important medical event requiring intervention to prevent these outcomes.

    Time frame: From Day 1 until 30 days after last dose (up to approximately 42 months)

  2. Number of Participants With Abnormalities in Vital Signs

    Vital signs heart rate (HR) (beats/min), systolic blood pressure (SBP) (mmHG), and diastolic blood pressure (DBP) (mmHg).

    Time frame: From Day 1 until 30 days after last dose (up to approximately 42 months)

  3. Number of Participants With Grade 3 or Grade 4 Laboratory Abnormalities

    Blood samples were collected to assess laboratory parameters. Grade 3 = Severe laboratory abnormality Grade 4 = Life-threatening or very severe laboratory abnormality

    Time frame: From Day 1 until 30 days after last dose (up to approximately 42 months)

07

Results

Posted Mar 20, 2026

Participant flow

Participant flow — Overall Study
MilestoneDEUC 12mg QD - DEUC 12mg QDDEUC 6mg BID - DEUC 6mg BIDDEUC 3mg BID - DEUC 3mg BIDPBO BID - DEUC 12mg QDPBO BID - DEUC 6mg BIDPBO BID - DEUC 3mg BID
Started587367212121
Completed3544428139
Not completed23292513812
Withdrew: Other reasons111111645
Withdrew: Withdrawal by subject364522
Withdrew: Site terminated by sponsor011000
Withdrew: Pregnancy001000
Withdrew: Lost to follow-up202001
Withdrew: Lack of efficacy241021
Withdrew: Death001000
Withdrew: Adverse event574203

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events and Treatment Emergent Serious Adverse Events

A Treatment-Emergent Adverse Event (TEAE) is any untoward medical occurrence that begins or worsens after the first dose of study treatment, including any unfavorable sign, symptom, disease, or abnormal lab finding, whether or not related to the product, and may include worsening of pre-existing conditions. A Serious Adverse Event (SAE) is any untoward medical occurrence that results in death, is life-threatening, requires or prolongs hospitalization, causes persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect, or is considered an important medical event requiring intervention to prevent these outcomes.

Time frame:
From Day 1 until 30 days after last dose (up to approximately 42 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events and Treatment Emergent Serious Adverse Events
ParticipantsDEUC 12mg QD - DEUC 12mg QDDEUC 6mg BID - DEUC 6mg BIDDEUC 3mg BID - DEUC 3mg BIDPBO BID - DEUC 12mg QDPBO BID - DEUC 6mg BIDPBO BID - DEUC 3mg BID
Treatment Emergent Adverse Events516362211918
Treatment Emergent Serious Adverse Events13911403
PrimaryNumber of Participants With Abnormalities in Vital Signs

Vital signs heart rate (HR) (beats/min), systolic blood pressure (SBP) (mmHG), and diastolic blood pressure (DBP) (mmHg).

Time frame:
From Day 1 until 30 days after last dose (up to approximately 42 months)
Reported as:
Count of participants · Participants
Number of Participants With Abnormalities in Vital Signs
ParticipantsDEUC 12mg QD - DEUC 12mg QDDEUC 6mg BID - DEUC 6mg BIDDEUC 3mg BID - DEUC 3mg BIDPBO BID - DEUC 12mg QDPBO BID - DEUC 6mg BIDPBO BID - DEUC 3mg BID
HR VALUE > 100 AND CHANGE FROM BASELINE > 30211011
HR VALUE < 55 AND CHANGE FROM BASELINE < -15000000
SBP VALUE > 140 AND CHANGE FROM BASELINE > 20479202
SBP VALUE < 90 AND CHANGE FROM BASELINE < -20000000
DBP VALUE > 90 AND CHANGE FROM BASELINE > 1071013232
DBP VALUE < 55 AND CHANGE FROM BASELINE < -10000000
PrimaryNumber of Participants With Grade 3 or Grade 4 Laboratory Abnormalities

Blood samples were collected to assess laboratory parameters. Grade 3 = Severe laboratory abnormality Grade 4 = Life-threatening or very severe laboratory abnormality

Time frame:
From Day 1 until 30 days after last dose (up to approximately 42 months)
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 or Grade 4 Laboratory Abnormalities
ParticipantsDEUC 12mg QD - DEUC 12mg QDDEUC 6mg BID - DEUC 6mg BIDDEUC 3mg BID - DEUC 3mg BIDPBO BID - DEUC 12mg QDPBO BID - DEUC 6mg BIDPBO BID - DEUC 3mg BID
HEMOGLOBIN (G/L) GRADE 3021001
LYMPHOCYTES (10^9/L) GRADE 33310203
LYMPHOCYTES (10^9/L) GRADE 4000011
NEUTROPHILS (10^9/L) GRADE 3332020
NEUTROPHILS (10^9/L) GRADE 4000000
PLATELETS (10^9/L) GRADE 3001000
PLATELETS (10^9/L) GRADE 4000000
LEUKOCYTES (10^9/L) GRADE 3210011
LEUKOCYTES (10^9/L) GRADE 4000000
ALBUMIN (G/L) GRADE 3000000
ALKALINE PHOSPHATASE (IU/L) GRADE 3000000
ALKALINE PHOSPHATASE (IU/L) GRADE 4000000
ALANINE AMINOTRANSFERASE (U/L) GRADE 3101110
ALANINE AMINOTRANSFERASE (U/L) GRADE 4000000
ASPARTATE AMINOTRANSFERASE (U/L) GRADE 3101100
ASPARTATE AMINOTRANSFERASE (U/L) GRADE 4000000
BILIRUBIN (UMOL/L) GRADE 3000000
BILIRUBIN (UMOL/L) GRADE 4000000
CREATINE KINASE (IU/L) GRADE 3201000
CREATINE KINASE (IU/L) GRADE 4000010
CREATININE (UMOL/L) GRADE 3001000
CREATININE (UMOL/L) GRADE 4000000
GAMMA GLUTAMYL TRANSFERASE (U/L) GRADE 3201100
GAMMA GLUTAMYL TRANSFERASE (U/L) GRADE 4001000
GLUCOSE (MMOL/L) GRADE 3000000
GLUCOSE (MMOL/L) GRADE 4000000
HYPERCALCEMIA GRADE 3000000
HYPERCALCEMIA GRADE 4000000
HYPERKALEMIA GRADE 3001000
HYPERKALEMIA GRADE 4000000
HYPERMAGNESEMIA GRADE 3000000
HYPERMAGNESEMIA GRADE 4000000
HYPERNATREMIA GRADE 3000000
HYPERNATREMIA GRADE 4000000
HYPOCALCEMIA GRADE 3111000
HYPOCALCEMIA GRADE 4000000
HYPOKALEMIA GRADE 3111010
HYPOKALEMIA GRADE 4010000
HYPOMAGNESEMIA GRADE 3101000
HYPOMAGNESEMIA GRADE 4000000
HYPONATREMIA GRADE 3001000
HYPONATREMIA GRADE 4000000

Adverse events

Collected over All cause mortality was collected from first dose (Day 1) until study completion (up to approximately 312 weeks). AEs and SAEs were collected from first dose (Day 1) till 30 days after last dose (up to approximately 42 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DEUC 12mg QD - DEUC 12mg QD0/58 (0%)13/58 (22.4%)43/58 (74.1%)
DEUC 6mg BID - DEUC 6mg BID0/73 (0%)9/73 (12.3%)53/73 (72.6%)
DEUC 3mg BID - DEUC 3mg BID1/67 (1.5%)11/67 (16.4%)51/67 (76.1%)
PBO BID - DEUC 12mg QD0/21 (0%)4/21 (19%)16/21 (76.2%)
PBO BID - DEUC 6mg BID0/21 (0%)0/21 (0%)16/21 (76.2%)
PBO BID - DEUC 3mg BID0/21 (0%)3/21 (14.3%)16/21 (76.2%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
EventDEUC 12mg QD - DEUC 12mg QDDEUC 6mg BID - DEUC 6mg BIDDEUC 3mg BID - DEUC 3mg BIDPBO BID - DEUC 12mg QDPBO BID - DEUC 6mg BIDPBO BID - DEUC 3mg BID
ColitisGastrointestinal disorders0/580/730/671/210/210/21
Non-cardiac chest painGeneral disorders0/580/730/671/210/210/21
AppendicitisInfections and infestations2/580/730/670/210/211/21
Infected dermal cystInfections and infestations0/580/730/671/210/210/21
Fracture displacementInjury, poisoning and procedural complications0/580/730/671/210/210/21
Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/580/730/670/210/211/21
Adnexa uteri cystReproductive system and breast disorders0/580/730/670/210/211/21
AsthmaRespiratory, thoracic and mediastinal disorders0/581/730/671/210/210/21
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders2/581/731/670/210/210/21
COVID-19 pneumoniaInfections and infestations1/582/731/670/210/210/21
Most frequent other events
Showing 10 of 38
Most frequent other events
EventDEUC 12mg QD - DEUC 12mg QDDEUC 6mg BID - DEUC 6mg BIDDEUC 3mg BID - DEUC 3mg BIDPBO BID - DEUC 12mg QDPBO BID - DEUC 6mg BIDPBO BID - DEUC 3mg BID
COVID-19Infections and infestations16/5821/7324/674/214/215/21
NasopharyngitisInfections and infestations13/5810/7313/674/215/211/21
Urinary tract infectionInfections and infestations8/5816/7311/673/213/213/21
Upper respiratory tract infectionInfections and infestations11/5811/7313/672/212/212/21
DiarrhoeaGastrointestinal disorders3/585/733/671/214/211/21
Gastrooesophageal reflux diseaseGastrointestinal disorders1/584/732/673/211/210/21
PharyngitisInfections and infestations1/583/734/671/213/212/21
HeadacheNervous system disorders7/585/737/673/211/212/21
AcneSkin and subcutaneous tissue disorders3/583/731/673/212/212/21
Herpes zosterInfections and infestations3/589/735/671/211/212/21

Baseline characteristics

Age, Continuous
Age, Continuous(years)DEUC 12mg QD - DEUC 12mg QDDEUC 6mg BID - DEUC 6mg BIDDEUC 3mg BID - DEUC 3mg BIDPBO BID - DEUC 12mg QDPBO BID - DEUC 6mg BIDPBO BID - DEUC 3mg BIDTotal
Mean38.0 ± 9.5643.4 ± 11.8741.1 ± 12.3244.6 ± 13.3941.5 ± 14.2644.1 ± 12.9041.6 ± 12.04
Sex: Female, Male
Sex: Female, Male(Participants)DEUC 12mg QD - DEUC 12mg QDDEUC 6mg BID - DEUC 6mg BIDDEUC 3mg BID - DEUC 3mg BIDPBO BID - DEUC 12mg QDPBO BID - DEUC 6mg BIDPBO BID - DEUC 3mg BIDTotal
Female516862191817235
Male75523426
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DEUC 12mg QD - DEUC 12mg QDDEUC 6mg BID - DEUC 6mg BIDDEUC 3mg BID - DEUC 3mg BIDPBO BID - DEUC 12mg QDPBO BID - DEUC 6mg BIDPBO BID - DEUC 3mg BIDTotal
Hispanic or Latino19202149780
Not Hispanic or Latino395346171114180
Unknown or Not Reported0000101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)DEUC 12mg QD - DEUC 12mg QDDEUC 6mg BID - DEUC 6mg BIDDEUC 3mg BID - DEUC 3mg BIDPBO BID - DEUC 12mg QDPBO BID - DEUC 6mg BIDPBO BID - DEUC 3mg BIDTotal
American Indian or Alaska Native24311112
Asian713753237
Native Hawaiian or Other Pacific Islander0000000
Black or African American65720121
White364443121415164
Unknown0000000
Others77713227
08

Study locations

98 sites
  • Local Institution - 0077
    Birmingham, Alabama 35233-1913, United States
  • Local Institution - 0030
    El Cajon, California 92020, United States
  • Local Institution - 0049
    Torrance, California 90502, United States
  • Local Institution - 0074
    New Haven, Connecticut 06520, United States
  • Local Institution - 0115
    Aventura, Florida 33180, United States
  • Local Institution - 0044
    Brandon, Florida 33511, United States
  • Local Institution - 0140
    Gainesville, Florida 32603, United States
  • Local Institution - 0133
    Orlando, Florida 32835, United States
  • Local Institution - 0032
    Ormond Beach, Florida 32174-1139, United States
  • Local Institution - 0048
    Tampa, Florida 33613, United States
  • Local Institution - 0094
    Atlanta, Georgia 30303, United States
  • Local Institution - 0050
    Lawrenceville, Georgia 30046, United States
  • Local Institution - 0123
    Brooklyn, New York 11201, United States
  • Local Institution - 0131
    New York, New York 10016, United States
  • Local Institution - 0071
    Chapel Hill, North Carolina 27599-7280, United States
  • Local Institution - 0031
    Charlotte, North Carolina 28204, United States
  • Local Institution - 0064
    Oklahoma City, Oklahoma 73104, United States
  • Local Institution - 0035
    Wyomissing, Pennsylvania 19610, United States
  • Local Institution - 0121
    Charleston, South Carolina 29425, United States
  • Local Institution - 0001
    Jackson, Tennessee 38305, United States
  • Local Institution - 0041
    Austin, Texas 78731-3146, United States
  • Tekton Research - Austin
    Austin, Texas 78745, United States
  • Local Institution - 0114
    Dallas, Texas 75390, United States
  • Local Institution - 0037
    Houston, Texas 77084, United States
  • Local Institution - 0046
    Mesquite, Texas 75150, United States
  • Clinica Adventista Belgrano
    Ciudad Autonoma de Buenos Aires, Buenos Aires 1430, Argentina
  • Local Institution - 0125
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1046, Argentina
  • Local Institution - 0098
    Rosario, Santa Fe Province 2000, Argentina
  • Local Institution - 0091
    San Miguel de Tucum, Tucumán Province T4000AXL, Argentina
  • Local Institution - 0100
    CABA, 1111, Argentina
  • Local Institution - 0122
    Córdoba, X5004FHP, Argentina
  • Local Institution - 0095
    Mendoza, 5500, Argentina
  • Local Institution - 0116
    Salvador, Estado de Bahia 40150-150, Brazil
  • Local Institution - 0118
    Goiߡ, Goiás 74110-120, Brazil
  • Local Institution - 0106
    Juiz de Fora, Minas Gerais 36010-570, Brazil
  • Local Institution - 0120
    Curitiba, Paraná 80030-110, Brazil
  • Local Institution - 0107
    Porto Alegre, Rio Grande do Sul 90480-000, Brazil
  • Local Institution - 0111
    São Bernardo do Campo, São Paulo 09715-090, Brazil
  • Local Institution - 0105
    São Paulo, 01228-200, Brazil
  • University of Calgary
    Calgary, Alberta T2N 4Z6, Canada
  • Local Institution - 0136
    Toronto, Ontario M5T 2S8, Canada
  • Local Institution - 0108
    Barranquilla, 0, Colombia
  • Local Institution - 0101
    Bogotá, 110221, Colombia
  • Local Institution - 0103
    Chía, 250001, Colombia
  • Local Institution - 0096
    Zipaquirá, 250252, Colombia
  • Local Institution - 0039
    Debrecen, 4032, Hungary
  • Local Institution - 0038
    Gyula, 5700, Hungary
  • Local Institution - 0045
    Szeged, 6725, Hungary
  • National Hospital Organization Chibahigashi National Hospital
    Chiba, Chiba 260-8712, Japan
  • Local Institution - 0092
    Kitakyushu, Fukuoka 807-8556, Japan
  • Local Institution - 0119
    Sapporo, Hokkaido 060-8604, Japan
  • Hokkaido University Hospital
    Sapporo, Hokkaido 060-8648, Japan
  • Local Institution - 0063
    Sendai, Miyagi 9808574, Japan
  • Local Institution - 0069
    Shimotsuke, Tochigi 329-0498, Japan
  • Local Institution - 0065
    Chuo-ku, Tokyo 104-8560, Japan
  • Local Institution - 0078
    Tokyo, 113-8431, Japan
  • Local Institution - 0066
    Tokyo, 162-8655, Japan
  • Local Institution - 0093
    Tokyo, 173-8610, Japan
  • Local Institution - 0080
    León, Guanajuato 37000, Mexico
  • Local Institution - 0086
    León, Guanajuato 37160, Mexico
  • Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.
    Zapopan, Jalisco 45070, Mexico
  • Local Institution - 0087
    Mexico City, Mexico City 06760, Mexico
  • Local Institution - 0084
    Monterrey, Nuevo León 64000, Mexico
  • Local Institution - 0082
    San Luis Potosí City, 78213, Mexico
  • Local Institution - 0025
    Bydgoszcz, 85-168, Poland
  • Local Institution - 0015
    Kościan, 64-000, Poland
  • Local Institution - 0014
    Krakow, 30-363, Poland
  • Local Institution - 0027
    Krakow, 31-011, Poland
  • Local Institution - 0018
    Krakow, 31-637, Poland
  • Local Institution - 0016
    Lublin, 20-607, Poland
  • Local Institution - 0024
    Poznan, 60-218, Poland
  • Local Institution - 0029
    Sosnowiec, 41-200, Poland
  • Local Institution - 0019
    Warsaw, 02-172, Poland
  • Local Institution - 0022
    Warsaw, 02-665, Poland
  • Local Institution - 0010
    Wroclaw, 50-363, Poland
  • Local Institution - 0023
    Wroclaw, 52-416, Poland
  • Local Institution - 0033
    Brasov, 500283, Romania
  • Local Institution - 0004
    Galati, 800578, Romania
  • Local Institution - 0002
    Râmnicu Vâlcea, 240277, Romania
  • Local Institution - 0056
    Kemerovo, 650066, Russia
  • Local Institution - 0072
    Novosibirsk, 630099, Russia
  • Local Institution - 0057
    Orenburg, 460018, Russia
  • Local Institution - 0062
    Saint Petersburg, 191045, Russia
  • Local Institution - 0058
    Saint Petersburg, 197341, Russia
  • Local Institution - 0070
    Smolensk, 214025, Russia
  • Local Institution - 0055
    Vladimir, 600005, Russia
  • Local Institution - 0068
    Yaroslavl, 150023, Russia
  • Local Institution - 0060
    Yaroslavl, 150030, Russia
  • Local Institution - 0061
    Yekaterinburg, 620043, Russia
  • Local Institution
    Seoul, 110-744, South Korea
  • Local Institution - 0053
    Suwon, 16499, South Korea
  • Local Institution - 0126
    Málaga, 29010, Spain
  • Local Institution - 0138
    Sabadell, 08208, Spain
  • Local Institution - 0124
    Seville, 41014, Spain
  • Local Institution - 0052
    Taichung, 40201, Taiwan
  • Local Institution - 0051
    Taipei, 10002, Taiwan
  • Local Institution
    Taipei, 10630, Taiwan
  • Local Institution - 0137
    Taipei, 110, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Mar 2025, 71 months.

Results were first posted in Mar 2026, 11 months after primary completion.

Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 71 months is above that.

Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2019
First posted
Apr 18, 2019
StartActual
Mar 26, 2019
Primary completionActual
Mar 21, 2025
CompletionActual
Mar 21, 2025
Results first posted
Mar 20, 2026
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03920267
Responsible party
Sponsor
First posted
Apr 18, 2019
Start date
Mar 26, 2019
Primary completion
Mar 21, 2025
Completion
Mar 21, 2025
Results posted
Mar 20, 2026
Last update
Mar 20, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion